Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses advancements in liquid biopsy for glioblastoma diagnosis and monitoring, focusing on tracking nucleosome epigenetic modifications. The research, presented at ISMRC 2025, suggests that these techniques could enhance the prognostic capabilities of cancer tests. The findings are supported by related articles that explore the implications of these advancements.
Price reaction · baseline $10.4 (2025-05-08T14:22:00.000Z) · hit during market hours · 3 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancements in liquid biopsy techniques for glioblastoma.
  • Potential for improved diagnosis and monitoring through epigenetic modifications.
  • Presentation at a significant conference (ISMRC 2025) highlights research credibility.

Full Press Release Details

Paper titled: Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking
Priscilla Van den Ackerveken, Jonathan Decarpentrie, Clotilde Hannart, Nathalie Hardat, Matteo Riva, Nathalie Donis, Fabienne George, Lionel d’Hondt, Jonathan Douxilfs, Marielle Herzog
Presented at ISMRC 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented research?

The research focuses on advancements in liquid biopsy for glioblastoma diagnosis and monitoring.

Where was the research presented?

The research was presented at ISMRC 2025.

What method is being tracked in this study?

The study tracks nucleosome epigenetic modifications.

What is the significance of the Nu.Q® Cancer Test?

The Nu.Q® Cancer Test shows prognostic value related to cancer diagnosis.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare liquid biopsy glioblastoma nucleosome modifications cancer diagnosis ISMRC 2025
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk